CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It

CVS Health has been a trending stock despite a recent one-month share decline of 6.1% versus the S&P’s 0.6% dip and a 2.3% gain for the Medical Services industry; Zacks highlights consensus estimates of $0.96 EPS for the current quarter (‑19.3% YoY), $6.62 for the current fiscal year (+22.1% YoY) and $7.14 for next year (+7.8%), with quarterly revenue estimates of roughly $102.7bn (≈+5.1% YoY) and fiscal revenue of $399.1bn (+7%). CVS topped expectations in the last reported quarter—$102.87bn revenue (+7.8% YoY) and $1.60 EPS—with revenue and EPS beats in each of the past four quarters, and Zacks assigns a Value grade of A indicating the stock trades at a discount to peers. Given recent upward revisions to full-year earnings but mixed near-term EPS momentum, Zacks rates CVS a #3 (Hold), implying it may perform roughly in line with the broader market in the near term.

Analysis

CVS Health has been a trending stock despite a one-month share decline of 6.1% versus the Zacks S&P 500 composite's -0.6% and the Zacks Medical Services industry's +2.3%, with the company characterized as both a drugstore chain and a pharmacy benefits manager. Zacks emphasizes earnings-estimate revisions as the key driver of near-term price action, and recent investor interest appears to reflect that focus.

Analyst consensus shows a current-quarter EPS estimate of $0.96 (-19.3% year-over-year) with a modest +0.8% revision over the last 30 days, while the fiscal-year consensus is $6.62 (+22.1%, +4% last 30 days) and next fiscal-year is $7.14 (+7.8%, -0.4% last month). CVS reported last-quarter revenue of $102.87 billion (+7.8% YoY) and EPS of $1.60 versus $1.09 a year ago, producing revenue and EPS surprises of +4.66% and +17.65% and four consecutive quarters of beats.

Zacks assigns CVS a Rank #3 (Hold) and a Value Style Score of A, indicating the shares trade at a discount to peers but may perform in line with the broader market near term. The juxtaposition of a near-term quarterly EPS decline against stronger full-year earnings revisions implies upside is contingent on continued positive revision momentum and confirming quarterly results; therefore upcoming guidance and consensus revision trends are the primary catalysts to watch.

Key Decisions for Investors

• Maintain a neutral/hold stance sized to portfolio risk given Zacks Rank #3 which implies in-line performance unless estimates move materially higher
• Consider incremental accumulation on meaningful pullbacks because of the A valuation grade and a four-quarter beat streak, but keep position size measured until next-quarter results confirm revenue and EPS momentum
• Monitor consensus revision flow and the company's next quarterly guidance as the key catalysts—if full-year EPS estimates continue to be revised upward, re-evaluate for an overweight allocation
• Employ downside protection or limit exposure in the near term to guard against volatility stemming from the current-quarter EPS decline and mixed market sentiment